Ticagrelor vs Clopidogrel: CV Events in Peripheral Artery Disease
Both ticagrelor and clopidogrel appear to have the same effect on patients with peripheral artery disease.
Both ticagrelor and clopidogrel appear to have the same effect on patients with peripheral artery disease.
Lipid-rich necrotic core in the proximal superficial femoral artery is associated with higher rates of clinical peripheral artery disease events.
At 1 year, primary patency was 82.3% for the drug-coated balloon group vs 70.9% for the percutaneous transluminal angioplasty group.
Patients with the highest levels of trimethylamine N-oxide had double the odds of dying during a 5-year period than those with the lowest levels.
Device technical success, device safety, and clinical procedure success were all 100% with a robotic-assisted platform in peripheral artery disease intervention.
Prolonged DAPT correlated with a reduced risk of a composite of death, myocardial infarction, or cerebrovascular accidents in patients with peripheral arterial disease.
PACUBA trial results revealed that paclitaxel-eluting balloon angioplasty yielded higher patency rates than standard percutaneous transluminal angioplasty.
Major cardiovascular adverse events and all-cause mortality were significantly reduced in patients without clinical CVD but with asymptomatic peripheral artery disease.
One-year data from the ACHILLES trial suggest that infrapopliteal sirolimus-eluting stenting is more effective for wound healing than plain balloon angioplasty.
IVUS-guided stenting demonstrated favorable patency, but poor life expectancy for patients with peripheral arterial disease.